Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
OVHIPEC-2 trial: what clinicians have said so far
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- NCT03772028 ↗
- Active, not recruiting
- The Netherlands Cancer Institute
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on OVHIPEC-2 (cisplatin in FIGO stage III epithelial ovarian cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on OVHIPEC-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 podcast episodes | |
| 2 posts on X |
The trial
ClinicalTrials.gov- Official title
- Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Ovarian Cancer
- Interventions
- cisplatin
- Arms
- conventional surgery · No intervention
- HIPEC · Experimental
- Enrollment
- 538 (estimated)
- Primary outcomes
- overall survival
- Sponsor
- The Netherlands Cancer Institute
- Start
- Jan 1, 2020
- Primary completion
- Apr 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT03772028 · updated Apr 8, 2026
Publications
linked from the registry- Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer. 2020 Jun;30(6):888-892. doi: 10.1136/ijgc-2020-001231. Epub 2020 Mar 23. PubMed 32205449